Long-term antiviral therapy for recurrent hepatitis C after liver transplantation in nonresponders: Biochemical, virological, and histological impact

Liver Transplantation

Volumn 15, Issue 1, 2009, Pages 54-63

  Walter, Thomas ^a,d   Scoazec, Jean Yves ^b,d   Guillaud, Olivier ^a,d   Hervieu, Valerie ^b,d   Chevallier, Philippe ^c,d   Boillot, Olivier ^a,d   Dumortier, Jérôme ^a,d  

^a EDOUARD HERRIOT HOSPITAL   (France)

^b HÔPITAL CIVIL   (France)

^c CROIX ROUSSE HOSPITAL   (France)

^d UNIVERSITÉ LYON 1   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA2B INTERFERON; ANTIVIRUS AGENT; CYCLOSPORIN; METHYLPREDNISOLONE; PEGINTERFERON; PEGINTERFERON ALPHA2B; RECOMBINANT ALPHA2B INTERFERON; RECOMBINANT ERYTHROPOIETIN; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; RIBAVIRIN; TACROLIMUS;

ACUTE GRAFT REJECTION; ADJUVANT THERAPY; ADULT; AGED; ANEMIA; ANTIVIRAL THERAPY; ARTICLE; ASTHENIA; BLOOD TRANSFUSION; CONTROLLED STUDY; DEPRESSION; DISEASE ASSOCIATION; DISEASE COURSE; DOSE RESPONSE; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG FEVER; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERANCE; DRUG WITHDRAWAL; FEMALE; HEART INFARCTION; HEPATITIS C; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; INCIDENCE; LEUKOPENIA; LIVER FIBROSIS; LIVER GRAFT REJECTION; LIVER TRANSPLANTATION; LONG TERM CARE; LOW DRUG DOSE; LYMPHOMA; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; OBSERVATIONAL STUDY; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; RECURRENT INFECTION; RETROSPECTIVE STUDY; SEPSIS; TREATMENT DURATION;

ADULT; AGED; ANTIVIRAL AGENTS; FEMALE; FIBROSIS; HEPATITIS C; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; RECURRENCE; RETROSPECTIVE STUDIES; TIME FACTORS; TREATMENT OUTCOME;

EID: 64049116615     PISSN: 15276465     EISSN: 15276473     Source Type: Journal    
DOI: 10.1002/lt.21652     Document Type: Article

References (53)

1. Adam R, McMaster P, O'Grady JG, Castaing D, Klempnauer JL, Jamieson N, et al. Evolution of liver transplantation in Europe: report of the European Liver Transplant Registry. Liver Transpl 2003;9:1231-1243.
2. Berenguer M, Lopez-Labrador FX, Wright TL. Hepatitis C and liver transplantation. J Hepatol 2001;35:666-678.
3. Wiesner RH, Sorrell M, Villamil F. Report of the first International Liver Transplantation Society expert panel consensus conference on liver transplantation and hepatitis C. Liver Transpl 2003;9:S1-S9.
4. Gane E. The natural history and outcome of liver transplantation in hepatitis C virus-infected recipients. Liver Transpl 2003;9:S28-S34.
5. Gane EJ, Portmann BC, Naoumov NV, Smith HM, Under-hill JA, Donaldson PT, et al. Long-term outcome of hepatitis C infection after liver transplantation. N Engl J Med 1996;334:815-820.
6. Feray C, Caccamo L, Alexander GJ, Ducot B, Gugenheim J, Casanovas T, et al. European collaborative study on factors influencing outcome after liver transplantation for hepatitis C. European Concerted Action on Viral Hepatitis (EUROHEP) Group. Gastroenterology 1999;117:619-625.
7. Forman LM, Lewis JD, Berlin JA, Feldman HI, Lucey MR. The association between hepatitis C infection and survival after orthotopic liver transplantation. Gastroenterology 2002;122:889-896.
8. Berenguer M, Prieto M, San Juan F, Rayon JM, Martinez F, Carrasco D, et al. Contribution of donor age to the recent decrease in patient survival among HCV-infected liver transplant recipients. Hepatology 2002;36:202-210.
9. Futagawa Y, Terasaki PI, Waki K, Cai J, Gjertson DW. No improvement in long-term liver transplant graft survival in the last decade: an analysis of the UNOS data. Am J Transplant 2006;6:1398-1406.
10. Carrion JA, Navasa M, Garcia-Retortillo M, Garcia-Pagan JC, Crespo G, Bruguera M, et al. Efficacy of antiviral therapy on hepatitis C recurrence after liver transplantation: a randomized controlled study. Gastroenterology 2007;132:1746-1756.
11. Samuel D. Hepatitis C, interferon, and risk of rejection after liver transplantation. Liver Transpl 2004;10:868-871.
12. Dumortier J, Scoazec JY, Chevallier P, Boillot O. Treatment of recurrent hepatitis C after liver transplantation: a pilot study of peginterferon alfa-2b and ribavirin combination. J Hepatol 2004;40:669-674.
13. Terrault NA. Treatment of recurrent hepatitis C in liver transplant recipients. Clin Gastroenterol Hepatol 2005; 3(suppl 2):S125-S131.
14. Berenguer M, Palau A, Aguilera V, Rayon JM, Juan FS, Prieto M. Clinical benefits of antiviral therapy in patients with recurrent hepatitis C following liver transplantation. Am J Transplant 2008;8:679-687.
15. Picciotto FP, Tritto G, Lanza AG, Addario L, De Luca M, Di Costanzo GG, et al. Sustained virological response to antiviral therapy reduces mortality in HCV reinfection after liver transplantation. J Hepatol 2007;46:459-465.
16. Shiffman ML, Hofmann CM, Contos MJ, Luketic VA, Sanyal AJ, Sterling RK, et al. A randomized, controlled trial of maintenance interferon therapy for patients with chronic hepatitis C virus and persistent viremia. Gastroenterology 1999;117:1164-1172.
17. Hoofnagle JH, Ghany MG, Kleiner DE, Doo E, Heller T, Promrat K, et al. Maintenance therapy with ribavirin in patients with chronic hepatitis C who fail to respond to combination therapy with interferon alfa and ribavirin. Hepatology 2003;38:66-74.
18. Di Bisceglie AM, Shiffman ML, Everson GT, Lindsay KL, Everhart JE, Wright EC, et al. Prolonged antiviral therapy with peginterferon to prevent complications of advanced liver disease associated with hepatitis C: results of the hepatitis C antiviral long-term treatment against cirrhosis (HALT-C) trial [abstract]. Hepatology 2007;46(suppl):LB1.
19. Giostra E, Kullak-Ublick GA, Keller W, Fried R, Vanlemmens C, Kraehenbuhl S, et al. Ribavirin/interferon-alpha sequential treatment of recurrent hepatitis C after liver transplantation. Transpl Int 2004;17:169-176.
20. Heydtmann M, Freshwater D, Dudley T, Lai V, Palmer S, Hubscher S, et al. Pegylated interferon alpha-2b for patients with HCV recurrence and graft fibrosis following liver transplantation. Am J Transplant 2006;6:825-833.
21. Kornberg A, Hommann M, Tannapfel A, Wagner T, Grube T, Schotte U, et al. Long-term combination of interferon alfa-2b and ribavirin for hepatitis C recurrence in liver transplant patients. Am J Transplant 2001;1:350-355.
22. Stravitz RT, Shiffman ML, Sanyal AJ, Luketic VA, Sterling RK, Heuman DM, et al. Effects of interferon treatment on liver histology and allograft rejection in patients with recurrent hepatitis C following liver transplantation. Liver Transpl 2004;10:850-858.
23. Walter T, Dumortier J, Guillaud O, Hervieu V, Paliard P, Scoazec JY, et al. Rejection under alpha interferon therapy in liver transplant recipients. Am J Transplant 2007;7: 177-184.
24. Walter T, Dumortier J, Guillaud O, Hervieu V, Scoazec JY, Boillot O. Factors influencing the progression of fibrosis in patients with recurrent hepatitis C after liver transplantation under antiviral therapy: a retrospective analysis of 939 liver biopsies in a single center. Liver Transpl 2007; 13:294-301.
25. French METAVIR Cooperative Study Group. Intraobserver and interobserver variations in liver biopsy interpretation in patients with chronic hepatitis C. Hepatology 1994;20: 15-20.
26. Banff schema for grading liver allograft rejection: an international consensus document. Hepatology 1997;25:658-663.
27. Demetris A, Adams D, Bellamy C, Blakolmer K, Clouston A, Dhillon AP, et al. Update of the International Banff Schema for Liver Allograft Rejection: working recommendations for the histopathologic staging and reporting of chronic rejection. An international panel. Hepatology 2000;31:792-799.
28. Sherman M, Cohen L, Cooper MA, Elkashab M, Feinman V, Fletcher D, et al. Clinical recommendations for the use of recombinant human erythropoietin in patients with hepatitis C virus being treated with ribavirin. Can J Gastroenterol 2006;20:479-485.
29. Berenguer M, Palau A, Fernandez A, Benlloch S, Aguilera V, Prieto M, et al. Efficacy, predictors of response, and potential risks associated with antiviral therapy in liver transplant recipients with recurrent hepatitis C. Liver Transpl 2006;12:1067-1076.
30. Ahmad J, Dodson SF, Demetris AJ, Fung JJ, Shakil AO. Recurrent hepatitis C after liver transplantation: a non-randomized trial of interferon alfa alone versus interferon alfa and ribavirin. Liver Transpl 2001;7:863-869.
31. De Vera ME, Smallwood GA, Rosado K, Davis L, Martinez E, Sharma S, et al. Interferon-alpha and ribavirin for the treatment of recurrent hepatitis C after liver transplantation. Transplantation 2001;71:678-686.
32. Firpi RJ, Abdelmalek MF, Soldevila-Pico C, Reed A, Hemming A, Howard R, et al. Combination of interferon alfa-2b and ribavirin in liver transplant recipients with histological recurrent hepatitis C. Liver Transpl 2002;8:1000-1006.
33. Narayanan Menon KV, Poterucha JJ, El-Amin OM, Burgart LJ, Kremers WK, Rosen CB, et al. Treatment of post-transplantation recurrence of hepatitis C with interferon and ribavirin: lessons on tolerability and efficacy. Liver Transpl 2002;8:623-629.
34. Samuel D, Bizollon T, Feray C, Roche B, Ahmed SN, Lemonnier C, et al. Interferon-alpha 2b plus ribavirin in patients with chronic hepatitis C after liver transplantation: a randomized study. Gastroenterology 2003;124:642-650.
35. Nair S, Khan S, Loss G, Eason J, Blazek J, Lipscomb J, et al. Treatment of recurrent hepatitis C in liver transplant recipients: is there any histologic benefit? Liver Transpl 2003;9:354-359.
36. Moreno Planas JM, Rubio Gonzalez E, Boullosa Grana E, Garrido Botella A, Barrios Peinado C, Lucena Poza JL, et al. Peginterferon and ribavirin in patients with HCV cirrhosis after liver transplantation. Transplant Proc 2005; 37:2207-2208.
37. Neumann U, Puhl G, Bahra M, Berg T, Langrehr JM, Neuhaus R, et al. Treatment of patients with recurrent hepatitis C after liver transplantation with peginterferon alfa-2B plus ribavirin. Transplantation 2006;82:43-47.
38. Burra P, Targhetta S, Pevere S, Boninsegna S, Guido M, Canova D, et al. Antiviral therapy for hepatitis C virus recurrence following liver transplantation: long-term results from a single center experience. Transplant Proc 2006;38:1127-1130.
39. Babatin M, Schindel L, Burak KW. Pegylated-interferon alpha 2b and ribavirin for recurrent hepatitis C after liver transplantation: from a Canadian experience to recommendations for therapy. Can J Gastroenterol 2005;19: 359-365.
40. Dumortier J, Ducos E, Scoazec JY, Chevallier P, Boillot O, Gagnieu MC. Plasma ribavirin concentrations during treatment of recurrent hepatitis C with peginterferon alpha-2b and ribavirin combination after liver transplantation. J Viral Hepat 2006;13:538-543.
41. Wang CS, Ko HH, Yoshida EM, Marra CA, Richardson K. Interferon-based combination anti-viral therapy for hepatitis C virus after liver transplantation: a review and quantitative analysis. Am J Transplant 2006;6:1586-1599.
42. Alberti AB, Belli LS, Airoldi A, de Carlis L, Rondinara G, Minola E, et al. Combined therapy with interferon and low-dose ribavirin in posttransplantation recurrent hepatitis C: a pragmatic study. Liver Transpl 2001;7:870-876.
43. Bizollon T, Ahmed SN, Radenne S, Chevallier M, Chevallier P, Parvaz P, et al. Long term histological improvement and clearance of intrahepatic hepatitis C virus RNA following sustained response to interferon-ribavirin combination therapy in liver transplanted patients with hepatitis C virus recurrence. Gut 2003;52:283-287.
44. Abdelmalek MF, Firpi RJ, Soldevila-Pico C, Reed AI, Hemming AW, Liu C, et al. Sustained viral response to interferon and ribavirin in liver transplant recipients with recurrent hepatitis C. Liver Transpl 2004;10:199-207.
45. Beckebaum S, Cicinnati VR, Zhang X, Malago M, Dirsch O, Erim Y, et al. Combination therapy with peginterferon alpha-2B and ribavirin in liver transplant recipients with recurrent HCV infection: preliminary results of an open prospective study. Transplant Proc 2004;36: 1489-1491.
46. Rodriguez-Luna H, Khatib A, Sharma P, De Petris G, Williams JW, Ortiz J, et al. Treatment of recurrent hepatitis C infection after liver transplantation with combination of pegylated interferon alpha2b and ribavirin: an open-label series. Transplantation 2004;77:190-194.
47. Ross AS, Bhan AK, Pascual M, Thiim M, Benedict Cosimi A, Chung RT. Pegylated interferon alpha-2b plus ribavirin in the treatment of post-liver transplant recurrent hepatitis C. Clin Transplant 2004;18:166-173.
48. Castells L, Vargas V, Allende H, Bilbao I, Luis Lazaro J, Margarit C, et al. Combined treatment with pegylated interferon (alpha-2b) and ribavirin in the acute phase of hepatitis C virus recurrence after liver transplantation. J Hepatol 2005;43:53-59.
49. Tisone G, Orlando G, Cardillo A, Palmieri G, Manzia TM, Baiocchi L, et al. Complete weaning off immunosuppression in HCV liver transplant recipients is feasible and favourably impacts on the progression of disease recurrence. J Hepatol 2006;44:702-709.
50. Bizollon T, Pradat P, Mabrut JY, Chevallier M, Adham M, Radenne S, et al. Benefit of sustained virological response to combination therapy on graft survival of liver transplanted patients with recurrent chronic hepatitis C. Am J Transplant 2005;5:1909-1913.
51. Yedibela S, Schuppan D, Muller V, Schellerer V, Tannapfel A, Hohenberger W, et al. Successful treatment of hepatitis C reinfection with interferon-alpha2b and ribavirin after liver transplantation. Liver Int 2005;25: 717-722.
52. Fernandez I, Meneu JC, Colina F, Garcia I, Munoz R, Castellano G, et al. Clinical and histological efficacy of pegylated interferon and ribavirin therapy of recurrent hepatitis C after liver transplantation. Liver Transpl 2006; 12:1805-1812.
53. Oton E, Barcena R, Moreno-Planas JM, Cuervas-Mons V, Moreno-Zamora A, Barrios C, et al. Hepatitis C recurrence after liver transplantation: viral and histologic response to full-dose PEG-interferon and ribavirin. Am J Transplant 2006;6:2348-2355.